immunization, and for this reason, the AAP recommends delaying rotavirus vaccination for 12 months after any in utero exposure to biologic DMARDs (except for certolizumab, which does not cross the placenta) The literature review identified no data on the effect of in utero rituximab exposure on later vaccine responses. Rituximab is a chimeric IgG1 molecule that can cross the placenta, and it has been associated with low or absent B lymphocyte levels in newborns who were exposed during the